⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Neuraxpharm and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Neuraxpharm
↗Langenfeld, Germany / Sant Joan Despí (Barcelona), Spain
Neuraxpharm is a leading European specialty pharmaceutical company dedicated to the treatment of central nervous system (CNS) disorders. With over 40 years of expertise, the company provides a comprehensive portfolio of psychiatric and neurological treatments, including originator brands, value-added medicines, generics, and biologic therapies.
The company operates with a strong patient-centric focus, addressing unmet needs in areas such as epilepsy, Parkinson's disease, schizophrenia, depression, anxiety, and multiple sclerosis. Neuraxpharm maintains a direct presence in over 20 European countries and leverages a global distribution network to reach patients worldwide.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$500M-$750M
Founded:1985
Ownership:private
Status:operating
FUNDING
Investors:Permira
PIPELINE
Stage:Phase 3
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb, Value-added medicines
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Permira
Acquired By:Permira (2020-09-01)
Subsidiaries:Neuraxpharm UK Limited, Neuraxpharm Bohemia s.r.o., Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi)
Key Partnerships:TG Therapeutics (Ex-US commercialization of BRIUMVI), Pharmathen (Co-development of long-acting injectables)
COMPETITION
Position:Leader
Competitors:Jazz Pharmaceuticals, Sana Biotechnology
LEADERSHIP
Key Executives:
Dr. Jörg-Thomas Dierks - CEO
Dr. Maximilian von Wülfing - COO
Lluís Pérez - CFO
Board Members:Olaf Krampe, Arthur Brothag, Duncan Reek, Mehmet Tar
LINKS
Website:neuraxpharm.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Neuraxpharm. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.